Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.46 |
| ▸ | CTH | P32929 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841190 | 0.98 | EPHX2 (0.56) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5840981 | 0.87 | NAALAD2 (0.50) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5840696 | 0.84 | L3MBTL1 (0.59) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5841196 | 0.83 | EPHX2 (0.56) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30843332 | 0.73 | L3MBTL1 (0.68) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1285620 | 0.73 | L3MBTL1 (0.68) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4682596 | 0.72 | L3MBTL1 (0.79) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17024865 | 0.71 | NAALAD2 (0.51) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5840984 | 0.70 | KDM6B (0.50) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13780257 | 0.70 | L3MBTL1 (0.62) | L3MBTL1EPHX2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | L3MBTL1 1285/4885EPHX2 1848/4885CYP3A4 1530/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | L3MBTL1 1375/4885EPHX2 1777/4885CYP3A4 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.